CR10122A - - Google Patents

Info

Publication number
CR10122A
CR10122A CR10122A CR10122A CR10122A CR 10122 A CR10122 A CR 10122A CR 10122 A CR10122 A CR 10122A CR 10122 A CR10122 A CR 10122A CR 10122 A CR10122 A CR 10122A
Authority
CR
Costa Rica
Application number
CR10122A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB0526232A priority Critical patent/GB0526232D0/en
Priority to GBGB0607088.2A priority patent/GB0607088D0/en
Priority to GB0607087A priority patent/GB0607087D0/en
Priority to GB0609902A priority patent/GB0609902D0/en
Priority to GBGB0620336.8A priority patent/GB0620336D0/en
Priority to GB0620337A priority patent/GB0620337D0/en
Priority to GB0620815A priority patent/GB0620815D0/en
Priority to GB0620816A priority patent/GB0620816D0/en
Priority to PCT/GB2006/004634 priority patent/WO2007068907A2/en
Application filed filed Critical
Publication of CR10122A publication Critical patent/CR10122A/es
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39133667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
CR10122A 2005-12-13 2008-06-27 CR10122A (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB0526232A GB0526232D0 (en) 2005-12-22 2005-12-22 Vaccine
GBGB0607088.2A GB0607088D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0607087A GB0607087D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
PCT/GB2006/004634 WO2007068907A2 (en) 2005-12-13 2006-12-12 Vaccine compositions comprising a saponin adjuvant

Publications (1)

Publication Number Publication Date
CR10122A true CR10122A (es) 2008-08-21

Family

ID=39133667

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10119A CR10119A (es) 2005-12-13 2008-06-26
CR10122A CR10122A (es) 2005-12-13 2008-06-27

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR10119A CR10119A (es) 2005-12-13 2008-06-26

Country Status (37)

Country Link
US (9) US20090017059A1 (es)
EP (10) EP2382986A3 (es)
JP (7) JP5579387B2 (es)
KR (4) KR101418240B1 (es)
CN (6) CN103585623B (es)
AR (3) AR058592A1 (es)
AT (1) AT520415T (es)
AU (4) AU2006327041B2 (es)
BR (3) BRPI0620460B1 (es)
CA (5) CA2634885C (es)
CL (1) CL2013002106A1 (es)
CR (2) CR10119A (es)
CY (4) CY1112677T1 (es)
DK (5) DK1968631T3 (es)
EA (3) EA014649B1 (es)
ES (4) ES2630759T3 (es)
HK (1) HK1120230A1 (es)
HR (4) HRP20110685T1 (es)
HU (3) HUE032903T2 (es)
IL (5) IL191913A (es)
JO (1) JO2813B1 (es)
LT (3) LT1973564T (es)
MA (3) MA30062B1 (es)
MX (2) MX354843B (es)
MY (4) MY147495A (es)
NO (3) NO343981B1 (es)
NZ (4) NZ569168A (es)
PE (2) PE13052007A1 (es)
PH (1) PH12014502544A1 (es)
PL (3) PL1973564T3 (es)
PT (4) PT1968631E (es)
SG (1) SG168517A1 (es)
SI (5) SI3017827T1 (es)
TR (1) TR201900418T4 (es)
TW (4) TWI415622B (es)
UA (2) UA96934C2 (es)
WO (3) WO2007071710A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1946769T1 (sl) * 2000-06-29 2012-07-31 Smithkline Beecham Biolog Sestavek multivalentnega cepiva z zmanjšanim odmerkom Haemophilus influenzae tipa B
AT317267T (de) 2000-11-07 2006-02-15 Immunovaccine Technologies Inc Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
ES2630759T3 (es) * 2005-12-22 2017-08-23 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacáridos capsulares de Streptococcus pneumoniae
KR101523108B1 (ko) * 2006-08-17 2015-05-26 더 유에이비 리서치 파운데이션 면역원성 pcpa 폴리펩티드 및 이의 용도
WO2008129559A2 (en) * 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
TW200914042A (en) * 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
AU2008267210B2 (en) * 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
EP2462949A3 (en) 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
AU2009208403A1 (en) 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
ES2553113T3 (es) * 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
KR20110009158A (ko) * 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2009143413A1 (en) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
MX2011006648A (es) 2008-12-17 2011-10-14 Novartis Ag Vacunas meningococales que incluyen receptor de hemoglobina.
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010227221B2 (en) * 2009-03-24 2015-01-22 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
CA2756533A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
DK2424562T3 (en) * 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
KR20110068831A (ko) * 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
EP2613805A2 (en) 2010-09-10 2013-07-17 Novartis AG Developments in meningococcal outer membrane vesicles
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2828844A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012156391A1 (en) * 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ
US9198977B2 (en) * 2012-01-30 2015-12-01 Serum Institute Of India Ltd. Immunogenic composition
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
EP2822586A1 (en) * 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
KR20130142574A (ko) 2012-06-20 2013-12-30 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2510281C2 (ru) * 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
DK2885007T3 (en) 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
RU2544168C1 (ru) * 2014-01-17 2015-03-10 Андрей Дмитриевич Протасов Способ формирования иммунологической памяти к антигенам streptococcus pneumoniae у пациентов с хронической обструктивной болезнью легких
CN106102770A (zh) * 2014-01-21 2016-11-09 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
RU2688831C2 (ru) * 2014-01-21 2019-05-22 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
EP3443983A1 (en) * 2014-02-14 2019-02-20 Pfizer Inc Immunogenic glycoprotein conjugates
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
CN103936842B (zh) * 2014-04-30 2016-03-23 重庆医科大学 肺炎链球菌溶血素突变体及其作为粘膜免疫佐剂的应用
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2600838C1 (ru) * 2015-06-08 2016-10-27 Андрей Дмитриевич Протасов Способ усиления активности факторов неспецифической защиты у пациентов с хронической обструктивной болезнью легких
KR20160146240A (ko) 2015-06-12 2016-12-21 전관구 염기성 계면활성제를 이용한 산화은나노 및 은나노 제조 방법
RU2018100123A3 (es) * 2015-07-21 2019-08-21
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
AR109290A1 (es) * 2016-08-05 2018-11-14 Sk Chemicals Co Ltd Composición conjugada neumocócica multivalente de polisacárido y proteína
EP3518965A1 (en) 2016-09-30 2019-08-07 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
WO2018080213A1 (ko) * 2016-10-28 2018-05-03 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
CN110198735A (zh) * 2017-01-20 2019-09-03 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
WO2018144438A1 (en) * 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018144799A1 (en) * 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine Microbial cells expressing streptococcal serotypes
WO2019050818A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
RU2121481C1 (ru) 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
DE68907045D1 (de) 1989-01-17 1993-07-15 Eniricerche Spa Synthetische peptide und deren verwendung als allgemeine traeger fuer die herstellung von immunogenischen konjugaten, die fuer die entwicklung von synthetischen impfstoffen geeignet sind.
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
DE69226167T2 (de) 1991-02-15 1998-11-12 Uab Research Foundation Strukturgen von pneumokokken-protein
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
CA2138137C (en) 1992-06-18 2004-11-09 R. John Collier Diphtheria toxin vaccines
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
AT241384T (de) * 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
CZ290331B6 (cs) 1993-11-17 2002-07-17 Laboratoires Om S. A. Glukosaminové disacharidy, způsob jejich přípravy a farmaceutický prostředek
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
ES2293708T3 (es) 1995-04-25 2008-03-16 Glaxosmithkline Biologicals S.A. Vacunas que contienen una saponina y un esterol.
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AU3399197A (en) 1996-06-18 1998-01-07 Alza Corporation Device for enhancing transdermal agent delivery or sampling
WO1998006734A1 (en) 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
ES2277362T5 (es) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
JP2002503087A (ja) 1996-11-12 2002-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニアのc3結合タンパク質
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
JP4153999B2 (ja) 1996-12-20 2008-09-24 アルザ・コーポレーション 経皮作用剤流量を強化するための組成物と方法
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
BR9812525A (pt) 1997-09-24 2000-07-25 Univ Minnesota Proteinase degradadora de complemento humano c3 de streptococcus pneumoniae
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
CN1285753A (zh) 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999051188A2 (en) 1998-04-07 1999-10-14 St. Jude Children's Research Hospital A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
AT461709T (de) 1998-04-07 2010-04-15 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
AU770378B2 (en) 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
WO2000017370A1 (en) 1998-09-24 2000-03-30 Regents Of The University Of Minnesota HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM $i(STREPTOCOCCUS PNEUMONIAE)
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
GB2359228A (en) 1998-11-17 2001-08-15 Schlumberger Technology Corp Transmitting information over a communication link
AU2027400A (en) 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
AT394489T (de) 1998-12-23 2008-05-15 Id Biomedical Corp Streptococcus antigene
EP1034792A1 (en) 1999-03-11 2000-09-13 Ingileif Jonsdottir Intranasal delivery of pneumococcal polysaccharide vaccines
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
HU229255B1 (en) 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
AU777856B2 (en) 1999-06-10 2004-11-04 Human Genome Sciences, Inc. Streptococcus pneumoniae proteins and vaccines
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
HU228706B1 (en) 2000-06-20 2013-05-28 Id Biomedical Corp Streptococcus antigens
SI1946769T1 (sl) * 2000-06-29 2012-07-31 Smithkline Beecham Biolog Sestavek multivalentnega cepiva z zmanjšanim odmerkom Haemophilus influenzae tipa B
WO2002012258A1 (en) 2000-08-04 2002-02-14 Corixa Corporation New immunoeffector compounds
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
FR2827199B1 (fr) 2001-07-10 2004-07-09 Centre Nat Rech Scient Procede et machine de fabrication ex situ de reseaux de biopuces basse et moyennes integration
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
BR0215588A (pt) 2002-02-04 2005-03-22 Corixa Corp Compostos imunoefetores
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
EP2258386A3 (en) 2002-08-02 2011-11-02 GlaxoSmithKline Biologicals S.A. Neisseria Vaccine composition
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN101818185B (zh) 2003-03-13 2016-05-25 葛兰素史密丝克莱恩生物有限公司 纯化细菌溶细胞素的方法
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CA2530364C (en) 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AT512670T (de) 2004-04-30 2011-07-15 Novartis Vaccines & Diagnostic Meningokokken-konjugat-impfung
BRPI0511026B1 (pt) 2004-05-11 2019-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Vws uso de um los neisserial, e, composição
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SI1868645T1 (sl) 2005-04-08 2012-04-30 Wyeth Llc Večvalentni pnevmokokni sestavek konjugata polisaharid-protein
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
EP1967204B1 (en) 2005-09-01 2013-10-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccination including serogroup c meningococcus
CA2628084A1 (en) 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
ES2630759T3 (es) 2005-12-22 2017-08-23 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacáridos capsulares de Streptococcus pneumoniae
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2008267210B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates

Also Published As

Publication number Publication date
PT1968631E (pt) 2015-07-20
US20100074922A1 (en) 2010-03-25
IL191913A (en) 2012-07-31
TWI465248B (zh) 2014-12-21
HK1120230A1 (en) 2011-12-09
PL2384765T3 (pl) 2017-05-31
SI3017827T1 (sl) 2019-01-31
JP5749689B2 (ja) 2015-07-15
CA2816182C (en) 2018-02-20
SI1962899T1 (sl) 2011-11-30
KR101418240B1 (ko) 2014-07-16
HRP20161681T1 (hr) 2017-01-13
WO2007071710A8 (en) 2008-09-04
BRPI0620460A2 (pt) 2011-11-16
US9107872B2 (en) 2015-08-18
HUE033081T2 (hu) 2017-11-28
US9884113B2 (en) 2018-02-06
IL219641A (en) 2017-10-31
WO2007071711A2 (en) 2007-06-28
PE10582007A1 (es) 2007-11-27
AR058592A1 (es) 2008-02-13
PL3017827T3 (pl) 2019-04-30
AU2006327040A1 (en) 2007-06-28
IL192084D0 (en) 2008-12-29
BRPI0620163A2 (pt) 2011-11-01
WO2007071711A3 (en) 2007-11-08
SI1968631T1 (sl) 2015-07-31
MA30066B1 (fr) 2008-12-01
KR20130103831A (ko) 2013-09-24
HRP20110685T1 (xx) 2011-10-31
EA014107B1 (ru) 2010-10-29
NZ569168A (en) 2012-02-24
EA014649B1 (ru) 2010-12-30
EP1968631B1 (en) 2015-04-08
EP1962899B1 (en) 2011-08-17
NO343981B1 (no) 2019-08-05
JP2009520759A (ja) 2009-05-28
HRP20161682T1 (hr) 2017-01-27
JP2009520761A (ja) 2009-05-28
US20160243219A1 (en) 2016-08-25
EP2382986A3 (en) 2012-08-22
TWI487534B (zh) 2015-06-11
JP5615323B2 (ja) 2014-10-29
SI1973564T1 (sl) 2017-02-28
PL1973564T3 (pl) 2017-04-28
CN101378779B (zh) 2015-09-02
MY147495A (en) 2012-12-14
IL191911D0 (en) 2008-12-29
JO2813B1 (en) 2014-09-15
NZ569077A (en) 2011-08-26
US10279033B2 (en) 2019-05-07
EP2384765B1 (en) 2016-11-23
TWI415622B (en) 2013-11-21
JP2014205673A (ja) 2014-10-30
EP2384765A2 (en) 2011-11-09
CN103585623B (zh) 2016-09-28
TW201350129A (en) 2013-12-16
ES2707499T3 (es) 2019-04-03
NO20082646L (no) 2008-09-16
US20180207262A1 (en) 2018-07-26
EP2402025A3 (en) 2012-03-07
US20190262447A1 (en) 2019-08-29
CN103251940A (zh) 2013-08-21
AU2006327040B2 (en) 2010-08-19
AT520415T (de) 2011-09-15
CA2634885A1 (en) 2007-06-28
US20150265702A1 (en) 2015-09-24
EP1973564B1 (en) 2016-11-09
TW200738257A (en) 2007-10-16
CA2634887C (en) 2016-01-19
KR101367237B1 (ko) 2014-03-14
KR20080081060A (ko) 2008-09-05
EP2382986A2 (en) 2011-11-02
BRPI0620460B1 (pt) 2019-08-13
IL191911A (en) 2015-09-24
IL211664D0 (en) 2011-05-31
MA30062B1 (fr) 2008-12-01
EP3020411A1 (en) 2016-05-18
EA200801367A1 (ru) 2008-12-30
AU2006327036B2 (en) 2012-11-15
MX2008008140A (es) 2008-09-24
CN101378778B (zh) 2013-02-06
EP1962899A2 (en) 2008-09-03
MX354843B (es) 2018-03-22
CA2634887A1 (en) 2007-06-28
AU2006327041B2 (en) 2010-08-26
CN110179974A (zh) 2019-08-30
EP3470080A1 (en) 2019-04-17
EA014165B1 (ru) 2010-10-29
PE13052007A1 (es) 2007-12-14
CA2634885C (en) 2016-04-19
CN103585623A (zh) 2014-02-19
PT1962899E (pt) 2011-10-19
NO20082718L (no) 2008-09-16
PT1973564T (pt) 2017-01-24
ES2539795T3 (es) 2015-07-06
CN101374548A (zh) 2009-02-25
CN101378778A (zh) 2009-03-04
US20090017059A1 (en) 2009-01-15
EP1973564A2 (en) 2008-10-01
CR10119A (es) 2008-07-29
IL191913D0 (en) 2009-02-11
UA96583C2 (uk) 2011-11-25
JP2012232985A (ja) 2012-11-29
EP3017827B1 (en) 2018-11-07
PT2384765T (pt) 2017-02-06
CA2816182A1 (en) 2007-06-28
WO2007071710A3 (en) 2007-11-29
MY160199A (en) 2017-02-28
MY150719A (en) 2014-02-28
AU2010241281A1 (en) 2010-11-25
AU2006327041A1 (en) 2007-06-28
CA2808919A1 (en) 2007-06-28
US20090017072A1 (en) 2009-01-15
CY1116407T1 (el) 2017-02-08
DK2384765T3 (en) 2017-01-09
CA2808919C (en) 2016-04-19
US20090010959A1 (en) 2009-01-08
ES2630759T3 (es) 2017-08-23
US20150190521A1 (en) 2015-07-09
CN101378779A (zh) 2009-03-04
EP3130348A1 (en) 2017-02-15
JP2012229228A (ja) 2012-11-22
LT3017827T (lt) 2019-01-10
US20180250389A9 (en) 2018-09-06
AR058707A1 (es) 2008-02-20
EA200801344A1 (ru) 2008-12-30
LT2384765T (lt) 2017-01-10
EP2384765A3 (en) 2012-06-20
IL219641D0 (en) 2012-06-28
BRPI0620163B1 (pt) 2019-08-13
JP5849125B2 (ja) 2016-01-27
KR20080081061A (ko) 2008-09-05
NZ596500A (en) 2013-05-31
EP3017827A1 (en) 2016-05-11
MY148141A (en) 2013-03-15
NZ569076A (en) 2011-08-26
JP2012211165A (ja) 2012-11-01
IL192084A (en) 2013-11-28
JP5792920B2 (ja) 2015-10-14
SG168517A1 (en) 2011-02-28
TW200738258A (en) 2007-10-16
DK1973564T3 (da) 2017-01-16
DK3017827T3 (en) 2019-02-18
NO20082647L (no) 2008-09-18
EP2402025A2 (en) 2012-01-04
KR20080081063A (ko) 2008-09-05
AR058706A1 (es) 2008-02-20
MA30065B1 (fr) 2008-12-01
ES2614938T3 (es) 2017-06-02
CY1112677T1 (xx) 2016-02-10
CY1118345T1 (el) 2017-06-28
KR101441368B1 (ko) 2014-09-24
JP5600337B2 (ja) 2014-10-01
KR101365001B1 (ko) 2014-02-21
CL2013002106A1 (es) 2014-03-07
AU2010241281B2 (en) 2012-12-06
JP5461838B2 (ja) 2014-04-02
DK1962899T3 (da) 2011-10-31
UA96934C2 (uk) 2011-12-26
KR20140036327A (ko) 2014-03-25
CN101374548B (zh) 2013-05-01
BRPI0620193A2 (pt) 2011-11-01
DK1968631T3 (da) 2015-06-15
HUE032903T2 (hu) 2017-11-28
WO2007071707A3 (en) 2007-09-13
PH12014502544A1 (en) 2015-12-14
CA2633772A1 (en) 2007-06-28
LT1973564T (lt) 2016-12-27
WO2007071707A2 (en) 2007-06-28
HRP20190037T1 (hr) 2019-02-22
EP1968631A2 (en) 2008-09-17
WO2007071710A2 (en) 2007-06-28
EA200801374A1 (ru) 2008-12-30
AU2006327036A1 (en) 2007-06-28
CY1118535T1 (el) 2017-07-12
TR201900418T4 (tr) 2019-02-21
HUE041979T2 (hu) 2019-06-28
JP5579387B2 (ja) 2014-08-27
JP2009520760A (ja) 2009-05-28
CA2633772C (en) 2015-09-15
SI2384765T1 (sl) 2017-03-31

Similar Documents

Publication Publication Date Title
EP1595685A1 (es)
DE502006007746D1 (es)
ECSDI056165S (es)
ECSMU055990U (es)
IN203075B (es)
DE602006013039D1 (es)
EP1544224A1 (es)
IN203999B (es)
ECSDI055928S (es)
ECSDI066661S (es)
FR2882923B1 (es)
CN1858219K1 (es)
EP1600483A1 (es)
DE502006008298D1 (es)
CR10119A (es)
IN214097B (es)
DE602006021727D1 (es)
HK1110211A1 (es)
ECSDI055892S (es)
CR10077A (es)
HK1121051A1 (es)
ECSDI056143S (es)
DE502006007781D1 (es)
CN2830302K5 (es)
ECSMU066687U (es)